Sugi Predict

Sugi Predict / Compounds / SCHEMBL442643

SCHEMBL442643

SCHEMBL442643

CCCC1CC(=O)OC(=O)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.46
▸ FYN P06241 1/20 0.42
▸ NOS3 P29474 1/20 0.38
▸ NOS1 P29475 1/20 0.38
▸ NOS2 P35228 1/20 0.38
▸ TSHR P16473 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HCAR2 Q8TDS4 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ AKT1 P31749 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ SIRT2 Q8IXJ6 1/20 0.32
▸ CHRM5 P08912 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ PPARG P37231 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3688744 0.86 CYP1A2 (0.56) CYP1A2TSHRALDH1A1HCAR2AKT1
SCHEMBL4072508 0.85 CYP1A2 (0.65) CYP1A2TSHRALDH1A1SIRT2TP53
SCHEMBL2220339 0.83 CYP1A2 (0.62) CYP1A2TSHRALDH1A1PPARGKMT2A
SCHEMBL14119910 0.83 CYP1A2 (0.62) CYP1A2TSHRALDH1A1PPARGKMT2A
SCHEMBL5159442 0.80 CYP1A2 (0.39) CYP1A2NOS3NOS1NOS2TSHR
SCHEMBL17834498 0.80 TLR4 (0.41) CYP1A2FYNNOS3NOS1NOS2
SCHEMBL17968954 0.80 TLR4 (0.41) CYP1A2FYNNOS3NOS1NOS2
SCHEMBL12641503 0.79 — —
SCHEMBL18263291 0.79 — —
SCHEMBL28363554 0.79 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117756447-A High-performance concrete in high-altitude large-temperature-difference environment and preparation method thereof 中铁二十局集团第三工程有限公司 2024-03-26 — — CN claimed
CN-117696019-A Plant fiber-based adsorption material and preparation method and application thereof 中国科学院赣江创新研究院 2024-03-15 — — CN claimed
CN-119504548-A Method for preparing buvaracetam intermediate by chemical-enzymatic method 尚科生物医药（上海）有限公司 2025-02-25 — — CN disclosed
CN-115340482-B Synthesis method of brivaracetam 四川诺非特生物药业科技有限公司 2024-05-14 — — CN disclosed
CN-112739683-B Preparation method of brivaracetam and intermediate thereof 上海宣泰医药科技股份有限公司 2024-04-16 — — CN disclosed
CN-117756447-A High-performance concrete in high-altitude large-temperature-difference environment and preparation method thereof 中铁二十局集团第三工程有限公司 2024-03-26 — — CN disclosed
CN-117696019-A Plant fiber-based adsorption material and preparation method and application thereof 中国科学院赣江创新研究院 2024-03-15 — — CN disclosed
US-11884623-B2 Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam DIVI'S LABORATORIES LTD. (IN) 2024-01-30 — — US disclosed
EP-4282971-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM Divi's Laboratories Limited (IN) 2023-11-29 — — EP disclosed
US-20230373914-A1 PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM DIVI'S LABORATORIES LTD. (IN) 2023-11-23 — — US disclosed
US-20230373914-A1 PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM DIVI'S LABORATORIES LTD. (IN) 2023-11-23 — — US disclosed
US-20110293699-A1 HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING COVIDIEN LP 2011-12-01 — — US disclosed
EP-2389896-A2 Hydrogel implants with varying degrees of crosslinking Tyco Healthcare Group LP (US) 2011-11-30 — — EP disclosed
EP-2389926-A2 Hydrogel implants with varying degrees of crosslinking Tyco Healthcare Group LP (US) 2011-11-30 — — EP disclosed
EP-2389895-A2 Hydrogel implants with varying degrees of crosslinking Tyco Healthcare Group LP (US) 2011-11-30 — — EP disclosed
EP-2389894-A2 Hydrogel implants with varying degrees of crosslinking Tyco Healthcare Group LP (US) 2011-11-30 — — EP disclosed
EP-2389925-A2 Hydrogel implant with varying degrees of crosslinking Tyco Healthcare Group LP (US) 2011-11-30 — — EP disclosed
US-20110253396-A1 INERT GAS FIRE-EXTINGUISHING SYSTEM FOR REDUCING THE RISK OF AN EXTINGUISHING FIRES IN A PROTECTED ROOM AMRONA AG (CH) 2011-10-20 — — US disclosed
US-20110258626-A1 NOTIFYING SOFTWARE COMPONENTS USING A SHARED PHYSICAL STORAGE MEDIUM VMWARE, INC. (US) 2011-10-20 — — US disclosed
EP-0454444-A1 Glutarimide derivatives and herbicides NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1991-10-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884623-B2 Process for the preparation of (R)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam BPGM, MGAM, HPD CYP1A2 144/4885FYN 4197/4885NOS3 1363/4885
US-20230373914-A1 PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM BPGM, MGAM, HPD CYP1A2 144/4885FYN 4197/4885NOS3 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.